Monoclonal antibodies such as Infliximab and Adalimumab inhibit atypical activation of NF-κB pathway by reducing TNF-α levels, which has the potential to relieve symptoms in critically ill patients with COVID-19 (116). This evidence concerns the gene TNF and COVID-19.